Zonisamide: Review of Recent Clinical Evidence for Treatment of Epilepsy

Shang Yeong Kwan, Yao Chung Chuang, Chin Wei Huang, Ta Cheng Chen, Shuo Bin Jou, Amitabh Dash

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Zonisamide is an orally administered antiepileptic drug that was first approved for clinical use in Japan in 1989. Since then, it has been licensed in Korea for a broad spectrum of epilepsies in adults and children, and in the USA for adjunctive therapy of adults with partial seizures, and in Europe for monotherapy of adults with newly diagnosed partial seizures and adjunctive therapy of adults and adolescents and children aged ≥6 years with partial seizures with or without secondary generalization. Zonisamide is a benzisoxazole derivative with a unique chemical structure, predictable dose-dependent pharmacokinetics, and multiple complementary mechanisms of action. Treatment with zonisamide is well tolerated and is not known to be associated with clinically significant drug-drug interactions, including with oral contraceptives or other antiepileptic drugs. There have been >2 million patient-years of experience with zonisamide for treatment of epilepsy, and this drug has International League Against Epilepsy level A evidence for efficacy/effectiveness as initial monotherapy for adults with partial-onset seizures. This review presents the evidence for zonisamide across the spectrum of epilepsy, with emphasis on real-world clinical practice and special populations of patients (children, elderly patients, and women of childbearing age) who are likely to be treated in daily clinical practice.

Original languageEnglish
Pages (from-to)683-691
Number of pages9
JournalCNS Neuroscience and Therapeutics
Volume21
Issue number9
DOIs
Publication statusPublished - 2015 Sep 1

Fingerprint

zonisamide
Epilepsy
Seizures
Anticonvulsants
Therapeutics
Korea
Oral Contraceptives
Drug Interactions
Pharmaceutical Preparations
Japan
Pharmacokinetics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Psychiatry and Mental health
  • Physiology (medical)
  • Pharmacology (medical)

Cite this

Kwan, Shang Yeong ; Chuang, Yao Chung ; Huang, Chin Wei ; Chen, Ta Cheng ; Jou, Shuo Bin ; Dash, Amitabh. / Zonisamide : Review of Recent Clinical Evidence for Treatment of Epilepsy. In: CNS Neuroscience and Therapeutics. 2015 ; Vol. 21, No. 9. pp. 683-691.
@article{a467d9bd97f44c108c518198159a59a1,
title = "Zonisamide: Review of Recent Clinical Evidence for Treatment of Epilepsy",
abstract = "Zonisamide is an orally administered antiepileptic drug that was first approved for clinical use in Japan in 1989. Since then, it has been licensed in Korea for a broad spectrum of epilepsies in adults and children, and in the USA for adjunctive therapy of adults with partial seizures, and in Europe for monotherapy of adults with newly diagnosed partial seizures and adjunctive therapy of adults and adolescents and children aged ≥6 years with partial seizures with or without secondary generalization. Zonisamide is a benzisoxazole derivative with a unique chemical structure, predictable dose-dependent pharmacokinetics, and multiple complementary mechanisms of action. Treatment with zonisamide is well tolerated and is not known to be associated with clinically significant drug-drug interactions, including with oral contraceptives or other antiepileptic drugs. There have been >2 million patient-years of experience with zonisamide for treatment of epilepsy, and this drug has International League Against Epilepsy level A evidence for efficacy/effectiveness as initial monotherapy for adults with partial-onset seizures. This review presents the evidence for zonisamide across the spectrum of epilepsy, with emphasis on real-world clinical practice and special populations of patients (children, elderly patients, and women of childbearing age) who are likely to be treated in daily clinical practice.",
author = "Kwan, {Shang Yeong} and Chuang, {Yao Chung} and Huang, {Chin Wei} and Chen, {Ta Cheng} and Jou, {Shuo Bin} and Amitabh Dash",
year = "2015",
month = "9",
day = "1",
doi = "10.1111/cns.12418",
language = "English",
volume = "21",
pages = "683--691",
journal = "CNS Neuroscience and Therapeutics",
issn = "1755-5930",
publisher = "Wiley-Blackwell",
number = "9",

}

Zonisamide : Review of Recent Clinical Evidence for Treatment of Epilepsy. / Kwan, Shang Yeong; Chuang, Yao Chung; Huang, Chin Wei; Chen, Ta Cheng; Jou, Shuo Bin; Dash, Amitabh.

In: CNS Neuroscience and Therapeutics, Vol. 21, No. 9, 01.09.2015, p. 683-691.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Zonisamide

T2 - Review of Recent Clinical Evidence for Treatment of Epilepsy

AU - Kwan, Shang Yeong

AU - Chuang, Yao Chung

AU - Huang, Chin Wei

AU - Chen, Ta Cheng

AU - Jou, Shuo Bin

AU - Dash, Amitabh

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Zonisamide is an orally administered antiepileptic drug that was first approved for clinical use in Japan in 1989. Since then, it has been licensed in Korea for a broad spectrum of epilepsies in adults and children, and in the USA for adjunctive therapy of adults with partial seizures, and in Europe for monotherapy of adults with newly diagnosed partial seizures and adjunctive therapy of adults and adolescents and children aged ≥6 years with partial seizures with or without secondary generalization. Zonisamide is a benzisoxazole derivative with a unique chemical structure, predictable dose-dependent pharmacokinetics, and multiple complementary mechanisms of action. Treatment with zonisamide is well tolerated and is not known to be associated with clinically significant drug-drug interactions, including with oral contraceptives or other antiepileptic drugs. There have been >2 million patient-years of experience with zonisamide for treatment of epilepsy, and this drug has International League Against Epilepsy level A evidence for efficacy/effectiveness as initial monotherapy for adults with partial-onset seizures. This review presents the evidence for zonisamide across the spectrum of epilepsy, with emphasis on real-world clinical practice and special populations of patients (children, elderly patients, and women of childbearing age) who are likely to be treated in daily clinical practice.

AB - Zonisamide is an orally administered antiepileptic drug that was first approved for clinical use in Japan in 1989. Since then, it has been licensed in Korea for a broad spectrum of epilepsies in adults and children, and in the USA for adjunctive therapy of adults with partial seizures, and in Europe for monotherapy of adults with newly diagnosed partial seizures and adjunctive therapy of adults and adolescents and children aged ≥6 years with partial seizures with or without secondary generalization. Zonisamide is a benzisoxazole derivative with a unique chemical structure, predictable dose-dependent pharmacokinetics, and multiple complementary mechanisms of action. Treatment with zonisamide is well tolerated and is not known to be associated with clinically significant drug-drug interactions, including with oral contraceptives or other antiepileptic drugs. There have been >2 million patient-years of experience with zonisamide for treatment of epilepsy, and this drug has International League Against Epilepsy level A evidence for efficacy/effectiveness as initial monotherapy for adults with partial-onset seizures. This review presents the evidence for zonisamide across the spectrum of epilepsy, with emphasis on real-world clinical practice and special populations of patients (children, elderly patients, and women of childbearing age) who are likely to be treated in daily clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84939262258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939262258&partnerID=8YFLogxK

U2 - 10.1111/cns.12418

DO - 10.1111/cns.12418

M3 - Review article

C2 - 26205514

AN - SCOPUS:84939262258

VL - 21

SP - 683

EP - 691

JO - CNS Neuroscience and Therapeutics

JF - CNS Neuroscience and Therapeutics

SN - 1755-5930

IS - 9

ER -